1. Mateo, C., Moreno, E., Amour, K., Lombardero, J., Harris, W., Perez, R., 1997. Humanization of a mouse monoclonal antibody that blocks the epidermal growth factor receptor: recovery of antagonistic activity. Immunotechnology 3 (1), 71–81.
2. Mateo, C., Lombardero, J., Moreno, E., Morales, A., Bombino, G., Coloma, J., Wims, L., Morrison, S.L., Perez, R., 2000. Removal of amphipathic epitopes from genetically engineered antibodies: production of modified immunoglobulins with reduced immunogenicity. Hybridoma 19 (6), 463–471.
3. Carr, A., Mullet, A., Mazorra, Z., Vazquez, A.M., Alfonso, M., Mesa, C., Rengifo, E., Perez, R., Fernandez, L.E., 2000. A mouse IgG1 monoclonal antibody specific for Nglycolyl GM3 ganglioside recognized breast and melanoma tumors. Hybridoma 19 (3), 241–247.
4. de Leon, J., Fernandez, A., Clavell, M., Labrada, M., Bebelagua, Y., Mesa, C., Fernandez, L.E., 2008. Differential influence of the tumour-specific non-human sialic acid containing GM3 ganglioside on CD4+CD25− effector and naturally occurring CD4+CD25+ regulatory T cells function. Int. Immunol. 20 (4), 591–600.
5. de Leon, J., Fernandez, A., Mesa, C., Clavel, M., Fernandez, L.E., 2006. Role of tumourassociated N-glycolylated variant of GM3 ganglioside in cancer progression: effect over CD4 expression on T cells. Cancer Immunol. Immunother. 55 (4), 443–450.
6. Marquina, G., Waki, H., Fernandez, L.E., Kon, K., Carr, A., Valiente, O., Perez, R., Ando, S., 1996. Gangliosides expressed in human breast cancer. Cancer Res. 56 (22), 5165–5171.
7. Carr, A., Mesa, C., del Carmen Arango, M., Vazquez, A.M., Fernandez, L.E., 2002. In vivo and in vitro anti-tumor effect of 14F7 monoclonal antibody. Hybrid. Hybridomics 21 (6), 463–468.